Cadrenal Therapeutics, Inc.
Valuation Based on our probability-adjusted DCF model that takes into account potential future revenues from tecarfarin in LVAD, ESKD+AFib, and mechanical heart valves, CVKD is valued at $30.00/share. This model is highly dependent on the continued clinical success of tecarfarin and will be adjusted accordingly based on future clinical results. Stand out Based on our…